Department of Psychiatry, Center for Brain Health, School of Medicine, New York, NY, USA.
Neurodegener Dis. 2010;7(1-3):131-5. doi: 10.1159/000289222. Epub 2010 Mar 3.
Preclinical diagnosis of Alzheimer's disease (AD) is one of the major challenges for the prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic changes, but also to monitor progression and therapeutics. PET neuroimaging can reliably assess aspects of the molecular biology and neuropathology of AD. The aim of this article is to review the use of FDG-PET and amyloid PET imaging in the early detection of AD.
阿尔茨海默病（AD）的临床前诊断是 AD 预防的主要挑战之一。不仅需要 AD 生物标志物来揭示临床前的病理变化，还需要监测疾病进展和治疗效果。正电子发射断层扫描（PET）神经影像学可以可靠地评估 AD 的分子生物学和神经病理学的各个方面。本文旨在综述 FDG-PET 和淀粉样蛋白 PET 成像在 AD 早期检测中的应用。
